Product News

Share this article:
The FDA issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease, comparing anti-reflux surgery with either Prilosec (omeprazole) (SOPRAN study) or Nexium (LOTUS study) treatment. AstraZeneca agrees with the FDA conclusion which states "FDA continues to conclude that long-term use of these drugs is not likely to be associated with an increased risk of heart problems. FDA recommends that healthcare providers continue to prescribe, and patients continue to use, these products as described in the labeling for the two drugs." AstraZeneca also supports the conclusion made by the FDA that the overall benefit/risk profiles of omeprazole and Nexium remain unchanged. AstraZeneca continues to be confident in the safety profiles of omeprazole and Nexium.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.